Discovery of PF-07220060, a potent and selective CDK4 inhibitor

被引：1
|
作者：
Anders, Lars
Gallego, Gary
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-ND12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ND12
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Preclinical evaluation of TQB3616, a highly potent and selective small-molecule CDK4/6 inhibitor
    Xu Zhaobing
    Hu Lihong
    Liu Yingchun
    Ding, Charles Z.
    Zhu, Xiaoyu
    Chen, Chen
    Zhu, Yusong
    Wu, Jiahu
    Wu, Dongdong
    Chen, Shuhui
    Zhang, Xiquan
    Yang, Ling
    Tian, Xin
    CANCER RESEARCH, 2018, 78 (13)
  • [22] Design, synthesis and biological assessment of novel CDK4 inhibitor with potent anticancer activity
    Li, Yongtao
    Du, Renle
    Nie, Yongwei
    Wang, Tianqi
    Ma, Yakun
    Fan, Yan
    BIOORGANIC CHEMISTRY, 2021, 109
  • [23] CDKI-15, a novel and highly selective CDK4/6 inhibitor: discovery, in vitro and in vivo anticancer efficacy
    Tadesse, Solomon
    Bantie, Laychiluh
    Tomusange, Khamis
    Islam, Saiful
    Rahaman, Muhammed H.
    Noll, Benjamin
    Lam, Frankie
    Yu, Mingfeng
    Wang, Shudong
    CANCER RESEARCH, 2017, 77
  • [24] Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors
    Cho, Young Shin
    Angove, Hayley
    Brain, Christopher
    Chen, Christine Hiu-Tung
    Cheng, Hong
    Cheng, Robert
    Chopra, Rajiv
    Chung, Kristy
    Congreve, Miles
    Dagostin, Claudio
    Davis, Deborah J.
    Felten, Ruth
    Giraldes, John
    Hiscock, Steven D.
    Kim, Sunkyu
    Kovats, Steven
    Lagu, Bharat
    Lewry, Kim
    Loo, Alice
    Lu, Yipin
    Luzzio, Michael
    Maniara, Wiesia
    McMenamin, Rachel
    Mortenson, Paul N.
    Benning, Rajdeep
    O'Reilly, Marc
    Rees, David C.
    Shen, Junqing
    Smith, Troy
    Wang, Yaping
    Williams, Glyn
    Woolford, Alison J. -A.
    Wrona, Wojciech
    Xu, Mei
    Yang, Fan
    Howard, Steven
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (06): : 445 - 449
  • [25] Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor
    Yamakawa, Hiroko
    Mizutani, Akio
    Arikawa, Yasuyoshi
    Ebara, Shunsuke
    Satoh, Yoshihiko
    Morishita, Daisuke
    CANCER SCIENCE, 2023, 114 : 831 - 831
  • [26] Structure-based design of highly potent and selective Cdk4 inhibitors.
    Honma, T
    Hayashi, K
    Yoshizumi, T
    Ikeura, C
    Ikuta, M
    Suzuki-Takahashi, I
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U437 - U438
  • [27] Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
    Liang, Muh-Lii
    Chen, Chun-Han
    Liu, Yun-Ru
    Huang, Man-Hsu
    Lin, Yu-Chen
    Wong, Tai-Tong
    Lin, Sey-En
    Chu, Shing-Shiung
    Ding, Yi-Huei
    Hsieh, Tsung-Han
    CANCERS, 2020, 12 (12) : 1 - 17
  • [28] Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer
    Chen, Weijiao
    Ji, Minghui
    Cheng, Hao
    Zheng, Mingming
    Xia, Fei
    Min, Wenjian
    Yang, Huanaoyu
    Wang, Xiao
    Wang, Liping
    Cao, Lijuan
    Yuan, Kai
    Yang, Peng
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (22) : 15102 - 15122
  • [29] Inducible deletion of CDK4 and CDK6-deciphering CDK4/6 inhibitor effects in the hematopoietic system
    Maurer, Barbara
    Brandstoetter, Tania
    Kollmann, Sebastian
    Sexl, Veronika
    Prchal-Murphy, Michaela
    HAEMATOLOGICA, 2021, 106 (10) : 2624 - 2632
  • [30] Biomarkers for CDK4/6 inhibitor efficacy
    Sorscher, Steven
    BREAST JOURNAL, 2021, 27 (01): : 103 - 103
12345